Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megadose Hydroxocobalamin for Pernicious Anemia
NCT03372447Phase 4Completed
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydroxocobalamin in pernicious anemia (PA) and megaloblastic anemia, sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Primary endpoints: Hematologic response at 2 months and Duration of hematologic response at 6 months. Started Dec 2017; status: completed.
02
Drugs
hydroxocobalamin
03
Conditions
pernicious anemia (PA)megaloblastic anemia
Beyond the preview
Go deeper on NCT03372447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03372447.